A kit of parts includes a) gemcitabine or a pharmaceutically acceptable salt thereof and b) a cyclic dinucleotide or pharmaceutically acceptable salt thereof, wherein the cyclic dinucleotide or pharmaceutically acceptable salt thereof is an agonist of the receptor known as “stimulator of interferon genes” (STING), for use in the treatment of solid pancreatic cancer.

A kit of parts includes a) gemcitabine or a pharmaceutically acceptable salt thereof and b) a cyclic dinucleotide or pharmaceutically acceptable salt thereof, wherein the cyclic dinucleotide or pharmaceutically acceptable salt thereof is an agonist of the receptor known as “stimulator of interferon genes” (STING), for use in the treatment of solid pancreatic cancer.

A kit of parts includes a) gemcitabine or a pharmaceutically acceptable salt thereof and b) a cyclic dinucleotide or pharmaceutically acceptable salt thereof, wherein the cyclic dinucleotide or pharmaceutically acceptable salt thereof is an agonist of the receptor known as “stimulator of interferon genes” (STING), for use in the treatment of solid pancreatic cancer.

Nicotinamide mononucleotide (NMN), a pharmaceutically acceptable derivative thereof, or a pharmaceutically acceptable salt thereof, are described for use thereof in the prevention and/or treatment of a back pain such as a lumbalgia (low back pain), a dorsalgia (severe back pain), or a cervicalgia (neck pain), preferably a chronic lumbalgia; as well as compositions that include the same.

Nicotinamide mononucleotide (NMN), a pharmaceutically acceptable derivative thereof, or a pharmaceutically acceptable salt thereof, are described for use thereof in the prevention and/or treatment of a back pain such as a lumbalgia (low back pain), a dorsalgia (severe back pain), or a cervicalgia (neck pain), preferably a chronic lumbalgia; as well as compositions that include the same.

A cyclic dinucleotide compound of Formula (I): ##STR00001##
wherein X.sub.1 is H or F; X.sub.2 is H or F; at least one among X.sub.1 and X.sub.2 is a fluorine atom; Z is OH, OR.sub.1, SH or SR.sub.1, wherein: R.sub.1 is Na or NH.sub.4, or R.sub.1 is an enzyme-labile group which provides OH or SH in vivo such as pivaloyloxymethyl; B.sub.1 and B.sub.2 are bases chosen from Adenine, Hypoxanthine or Guanine, and B.sub.1 is a different base than B.sub.2 and a pharmaceutically acceptable salt thereof. Pharmaceutical compositions including the cyclic dinucleotide, as well as their use in the treatment of a bacterial infection, a viral infection or a cancer are also described.

A cyclic dinucleotide compound of Formula (I): ##STR00001##
wherein X.sub.1 is H or F; X.sub.2 is H or F; at least one among X.sub.1 and X.sub.2 is a fluorine atom; Z is OH, OR.sub.1, SH or SR.sub.1, wherein: R.sub.1 is Na or NH.sub.4, or R.sub.1 is an enzyme-labile group which provides OH or SH in vivo such as pivaloyloxymethyl; B.sub.1 and B.sub.2 are bases chosen from Adenine, Hypoxanthine or Guanine, and B.sub.1 is a different base than B.sub.2 and a pharmaceutically acceptable salt thereof. Pharmaceutical compositions including the cyclic dinucleotide, as well as their use in the treatment of a bacterial infection, a viral infection or a cancer are also described.

A cyclic dinucleotide compound of Formula (I): ##STR00001##
wherein X.sub.1 is H or F; X.sub.2 is H or F; at least one among X.sub.1 and X.sub.2 is a fluorine atom; Z is OH, OR.sub.1, SH or SR.sub.1, wherein: R.sub.1 is Na or NH.sub.4, or R.sub.1 is an enzyme-labile group which provides OH or SH in vivo such as pivaloyloxymethyl; B.sub.1 and B.sub.2 are bases chosen from Adenine, Hypoxanthine or Guanine, and B.sub.1 is a different base than B.sub.2 and a pharmaceutically acceptable salt thereof. Pharmaceutical compositions including the cyclic dinucleotide, as well as their use in the treatment of a bacterial infection, a viral infection or a cancer are also described.

The present disclosure provides a compound having a STING agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases. The present disclosure relates to a compound represented by the formula (I): ##STR00001##
wherein each symbol is as defined in the description, or a salt thereof.

The present disclosure provides a compound having a STING agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases. The present disclosure relates to a compound represented by the formula (I): ##STR00001##
wherein each symbol is as defined in the description, or a salt thereof.